Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316160 · ClinicalTrials.gov registry record · Phase 4
Sexual Functioning Study With Antidepressants
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 347
- Enrollment target
NCT00316160 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 347 participants.
The verdict
NCT00316160, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 347 participants
- Enrollment target
Study Summary
Effects of two depression medication on sexual functioning
Interventions
- DRUG Bupropion Hydrochloride Extended-release
- DRUG Extended-release Venlafaxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 347 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00316160
The ClinicalTrials.gov registry entry for NCT00316160 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 347 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupropion Hydrochloride Extended-release is the first listed.
NCT00316160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00316160 about?
NCT00316160 is a clinical study titled "Sexual Functioning Study With Antidepressants". Effects of two depression medication on sexual functioning
What is the current status of trial NCT00316160?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 347 participants. The study started on 2004-09. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00316160?
The interventions under investigation include: Bupropion Hydrochloride Extended-release (DRUG), Extended-release Venlafaxine (DRUG).
Who is sponsoring clinical trial NCT00316160?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.